Hot Features
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopa... Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.6 | 0.63 | 0.58 | 4843 | 0.59114965 | CS |
| 4 | 0.02 | 3.44827586207 | 0.58 | 0.63 | 0.56 | 27669 | 0.57380274 | CS |
| 12 | 0.11 | 22.4489795918 | 0.49 | 0.64 | 0.44 | 25121 | 0.55124717 | CS |
| 26 | -0.02 | -3.22580645161 | 0.62 | 0.66 | 0.44 | 21128 | 0.55981899 | CS |
| 52 | -0.1 | -14.2857142857 | 0.7 | 0.88 | 0.44 | 22771 | 0.6669015 | CS |
| 156 | -0.14 | -18.9189189189 | 0.74 | 1.06 | 0.44 | 20087 | 0.6901871 | CS |
| 260 | 0.2 | 50 | 0.4 | 1.06 | 0.375 | 19286 | 0.65952653 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.